



LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

Healthcare Weekly News and Deals – August 22nd, 2025

1. Tempus AI (NASDAQ: TEM) acquires Paige for \$81.25M to Advance Digital Pathology with AI

The deal integrates Paige's FDA-cleared pathology AI applications and vast dataset of 7 million clinically annotated slides into Tempus' precision medicine platform. Paige's foundation model for cancer, developed with global diverse data, will accelerate Tempus' oncology AI initiatives and drug discovery efforts. CEO Eric Lefkowsky highlighted the acquisition's role in building the largest oncology foundation model, leveraging Paige's partnership with Memorial Sloan Kettering. Paige CEO Razik Yousfi emphasized the combined potential to transform cancer detection and treatment. The transaction, primarily paid in Tempus stock, includes assumption of Paige's Azure cloud commitments, expanding Tempus' technical team and pathology footprint. The merger aims to enhance AI-driven diagnostic insights for broader patient impact. ([Link](#))

2. CitiusTech acquires Health Data Movers, via its financial sponsors EQT Private Capital Asia, Bain Capital, and Ergo Partners to Boost Epic Integration Capabilities

The acquisition enhances CitiusTech's healthcare IT offerings with specialized expertise in Epic Systems implementation, data integration, and clinical workflow optimization. Health Data Movers brings proven capabilities in large-scale EMR program delivery and operational transformation, complementing CitiusTech's AI-powered solutions. The merger aims to help healthcare providers unify complex technology ecosystems and integrate automation into clinical operations. Both CEOs emphasized the combined potential to accelerate digital transformation and improve patient care through seamless data connectivity. The deal comes as health systems increasingly adopt Agentic AI and cloud solutions, with Epic serving as a foundational platform. The partnership will minimize implementation risks while scaling end-to-end solutions for providers. ([Link](#))

3. ProVerum Secures \$80M Series B Led by MVM Partners, Welcomes OrbiMed and ISIF to Advance Minimally Invasive BPH Treatment

ProVerum Limited, developer of the ProVee® System for treating benign prostatic hyperplasia (BPH), has closed an \$80 million Series B funding round led by MVM Partners, with new investors OrbiMed and the Ireland Strategic Investment Fund (ISIF), and support from existing backers including Gilde Healthcare Partners, Lightstone Ventures, Atlantic Bridge, and Enterprise Ireland. The funds will be used to prepare for commercialization of ProVerum's minimally invasive BPH treatment. MVM's Hugo Harrod and OrbiMed's Dina Chaya join the Board of Directors, strengthening investor-led guidance as the company advances its innovative medical technology. ([Link](#))

4. TigerConnect bolsters Smart Hospital Strategy with eVideon acquisition, via its financial sponsor Vista Equity Partners

The deal combines TigerConnect's clinical communication platform with eVideon's patient engagement technology to create integrated smart room solutions. The unified system aims to reduce nurse workload through automation while enhancing patient experiences with self-service

capabilities and real-time updates. Corewell Health, an early eVideon investor and customer, endorsed the merger for its potential to modernize care delivery. The acquisition supports TigerConnect's vision of a connected healthcare ecosystem that streamlines vendor management and improves operational efficiency. Solutions include virtual care support, nurse call systems, and predictive workflows designed for both legacy upgrades and new facilities. Leadership from both companies emphasized the platform's role in advancing digital maturity across health systems. ([Link](#))

5. CentralReach acquires AI.Measures and SpectrumAI to Pioneer Outcomes-Based Autism Care Platform

The acquisitions integrate AI.Measures' severity-adjusted assessment tools and SpectrumAI's predictive analytics and video capture technology into CentralReach's EMR, enabling providers to transition from fee-for-service to outcomes-based care models. Dr. Thomas Frazier joins as Chief Clinical Officer, bringing clinical rigor, while Ling Shao becomes SVP of Outcomes-Based Care to advance data-driven decision support. The combined platform offers real-time progress monitoring, payor-approved contracting frameworks, and individualized care planning for autism and IDD providers. CEO Chris Sullens emphasized the strategy's potential to align reimbursement with measurable quality-of-life improvements, giving providers flexible service delivery options within a single integrated system. The move accelerates CentralReach's Care360 initiative while maintaining standalone solution access during integration. ([Link](#))

6. Custom Health acquires PatchRx to Enhance Medication Adherence Through Connected Technology

The integration of PatchRx's smart pill bottle caps and remote monitoring tools will expand Custom Health's vertically integrated platform, offering real-time adherence data and proactive intervention for chronic condition management. PatchRx co-founders Andrew Aertker and Gavin Buchanan will join Custom Health, bringing expertise in hardware-enabled compliance tracking. The acquisition strengthens Custom Health's AdhereNet® platform, particularly for pain management patients using opioids, by combining dispensing with continuous monitoring. CEO Shane Bishop emphasized the role of connectivity in improving outcomes for the 60% of adults with chronic conditions. The deal aims to reduce costs through timely support and data-driven treatment adjustments. ([Link](#))

7. PathAI partners with Moffitt Cancer Center to Integrate AISight® Dx Digital Pathology Platform

The multi-year collaboration will deploy PathAI's cloud-based AISight® Dx platform across Moffitt's pathology programs, enhancing diagnostic accuracy and operational efficiency through AI-driven slide management and analysis. The partnership includes joint research initiatives, real-world data aggregation, and co-development of next-generation AI diagnostics to advance precision oncology. PathAI CEO Andy Beck emphasized the platform's role in supporting pathologists and unlocking novel insights, while Moffitt's Karen Lu highlighted the alignment with their mission to transform cancer care through innovation. The integration aims to accelerate clinical trials and biopharma collaborations while improving diagnostic speed and reproducibility in oncology workflows. ([Link](#))

8. Sonitor and Tagnos merge to Transform Healthcare Operations with Integrated RTLS and Workflow Platform

The strategic combination unites Sonitor's high-precision real-time location system with Tagnos's orchestration software to optimize asset tracking, patient flow, and staff safety. Zebra

Technologies' venture arm, now a Sonitor shareholder, endorsed the merger for its potential to enhance healthcare efficiency and safety. The integrated platform will automate processes like equipment management, infection control, and patient throughput while reducing clinician burnout. CEOs Matt Crane and Sheila Minton emphasized the merger's role in addressing operational challenges through actionable data and interoperability. Current customers will experience no disruption as the companies accelerate innovation for global healthcare markets. The merger aims to deliver end-to-end visibility and automation for improved care quality. ([Link](#))

9. [restor3d secures \\$104M Investment from Partners Group to Advance Personalized Orthopaedic Implants](#)

The funding includes \$65M in new equity from Partners Group and \$39M from existing shareholders, marking the company's first institutional investment. Proceeds will accelerate product innovation, commercial expansion, and broader access to AI-designed, 3D-printed implants for shoulder, hip, knee, foot, and ankle procedures. Partners Group will join restor3d's board, contributing operational expertise to support growth. The company, which partnered with 520+ surgeons across 740 hospitals in 2024, uses proprietary software and additive manufacturing to create patient-specific solutions. The investment aims to scale digital surgical planning tools and enhance personalized orthopaedic care delivery nationwide. ([Link](#))

10. [Residex.AI acquires Kevala to Integrate AI Workforce Management into Senior Care Platform](#)

The deal combines Residex's EHR and eMAR systems with Kevala's Quin™ AI platform for staffing optimization, addressing critical industry challenges like workforce shortages and regulatory pressures. The integrated solution will enable predictive scheduling based on resident acuity and staff qualifications, enhancing both clinical and operational efficiency. CEOs Chris Poelma (Residex) and Todd Owens (Kevala) emphasized the synergy between clinical documentation and workforce intelligence, creating a unified ecosystem for cost-effective, high-quality senior care. The acquisition positions Residex as a comprehensive provider of automated solutions for medication management, care planning, and now dynamic staffing, ultimately aiming to improve resident outcomes and operational sustainability. ([Link](#))

11. [Uwill acquires tbh to expand Student Mental Health and Basic Needs Support](#)

The acquisition integrates tbh's AI-driven platform—which connects students to resources for housing, food, transportation, and mental health—into Uwill's existing teletherapy and crisis services. This move addresses growing financial insecurities among college students while minimizing administrative burden for schools. Uwill, which previously acquired Virtual Care Group and Christie Campus Health, aims to provide holistic support without expanding staff. tbh co-founder Asaf Zilberfarb emphasized redefining holistic student success. The deal strengthens Uwill's position against competitors like TimelyCare and Mantra Health in a sector where demand persists despite stabilized mental health prevalence rates. Full platform integration is expected within 12 months. ([Link](#))

12. [The Cottages Group acquires Cardinal to Expand Disability Care Services in Minnesota](#)

The merger enhances The Cottages Group's geographic reach and workforce capacity while maintaining Cardinal's Rochester operations, name, and staff. With Cardinal CEO Jack Priggen retiring, The Cottages Group CEO Brittany Eriksmoen emphasized a seamless transition focused on preserving both organizations' core values and service continuity for developmental disability clients. The acquisition adds southern Minnesota locations to The Cottages Group's network,

reinforcing its commitment to residential and in-home care. Priggen endorsed the alignment of missions, ensuring community-based services remain uninterrupted. The strategic move strengthens resources and stability for employees and clients amid leadership changes. ([Link](#))

13. Oktibbeha County Sells OCH Regional Medical Center to Baptist Memorial Health Care for \$55M

The definitive agreement includes a \$96.8 million commitment from Baptist to upgrade facilities, technology, and physician recruitment at the Starkville hospital. All current employees in good standing will retain their positions, and existing service lines—including ambulance services—will continue uninterrupted. County Board of Supervisors President Marvell Howard hailed the sale as transformative for local healthcare access. The transaction is expected to finalize by September's end, ensuring continuity of care while expanding resources through Baptist's regional network. The deal reflects ongoing consolidation trends in rural healthcare, aiming to enhance service quality and sustainability for Mississippi communities. ([Link](#))

Venture and Other News

1. Cleveland Clinic, JobsOhio, and Private Family Office Lead \$20M Series A Investment in Method AI's Breakthrough Oncology Navigation Platform

Method AI, a medical technology company founded at Cleveland Clinic in 2021, has secured \$20 million in Series A funding to advance its surgical ultrasound platform for oncology procedures. The round was led by a private family office, with key participation from Cleveland Clinic and JobsOhio Growth Capital Fund. Method AI's technology uses 3D ultrasound and AI-generated surgical plans to help surgeons visualize deep subsurface anatomy, aiming to improve cancer-free survival rates and reduce healthcare costs. Its platform is still in development and not yet commercially available. ([Link](#))

2. Luna Diabetes raises \$23.6M Series A, led by Vensana Capital and with participation from Ascensia Diabetes Care, 2468 Ventures, Interlock Capital, Serpentine Ventures and Winklevoss Capital Management to Scale World's Smallest Overnight Insulin Pump

The funding will advance development and regulatory pathways for Luna's compact, automated insulin delivery system designed for nighttime use. Targeting insulin pen users with type 1 and type 2 diabetes, the pump operates during sleep—when 80% of glucose improvement occurs—without requiring full-time wear. Backed by Swiss Diabetes Venture Fund, Ascensia Diabetes Care, and Winklevoss Capital, the startup aims to reduce cost and complexity barriers to automated dosing. CEO John Sjölund, a type 1 diabetes patient and industry veteran, emphasized addressing unmet needs for millions underserved by current pumps. The capital will support manufacturing scale-up and ongoing pivotal trials initiated in 2024. ([Link](#))

3. Molecular You raises \$5M Series A Led by Voloridge and participation from Dynamic Leap to Scale Predictive Health Platform

The funding will expand the company's multi-omic health testing, which analyses 250+ biomarkers from a single blood draw to identify pre-symptomatic disease risks. Partnering with HealthQuest Esoterics, Molecular You's Lab Developed Test (LDT) now qualifies for reimbursement, boosting accessibility in clinical and direct-to-consumer channels. The platform provides personalized lifestyle recommendations to prevent conditions like Alzheimer's and pancreatic cancer, demonstrated by early detection success stories. CEO Jim Kean and CMO Dr. Murdoc Khaleghi

emphasized the platform's holistic approach compared to fragmented traditional diagnostics. Investors including Dynamic Leap back the company's planned expansion to 800+ biomarkers and broader disease coverage, aligning with the growing \$8.5B longevity sector. ([Link](#))

4. **Neurovalens secures £6M Led by Clarendon Fund Manager and with participation from Whiterock, IQ Capital Partners, ACF Investors and Innovation Ulster for Non-Invasive Neurotech**

The funding will scale sales of FDA-cleared wearable devices that use electrical stimulation to treat insomnia, anxiety, and PTSD. Led by the British Business Bank's Investment Fund for Northern Ireland and managed by Clarendon, the round included Whiterock, IQ Capital, and Innovation Ulster. CEO Dr. Jason McKeown emphasized expanding the product portfolio through additional regulatory approvals. The company has now raised ~£20M total, leveraging non-invasive neurostimulation to address global mental health challenges. Clarendon's Brian Cummings highlighted Neurovalens' significant milestones, including FDA clearances, as key to the investment decision. The capital accelerates commercial growth and technological innovation in the health tech sector. ([Link](#))